注射安进地舒单抗的注意事项

It is the first RANKL inhibitor approved by the FDA. The FDA approved denosumab for use in postmenopausal women with osteoporosis who are at high risk for fractures to help reduce the incidence of vertebral, non-vertebral and hip fractures in postmenopausal women with osteoporosis. Today, let’s take a look at the precautions for injecting Amgen denosumab.

For patients who are prone to hypocalcemia and mineral metabolism imbalance (such as those with a history of hypoparathyroidism, parathyroid surgery, malnutrition, thyroid surgery, small bowel resection, and severe renal insufficiency), it is necessary to closely monitor their creatinine and mineral levels in clinical practice, and instruct such patients to pay attention to the symptoms of hypocalcemia and to supplement adequate amounts of calcium and vitamin D. Hypocalcemia must therefore be corrected before denosumab therapy can be initiated.

Physicians should evaluate the need to continue denosumab therapy in patients who develop serious infections while taking denosumab. Patients who are concurrently taking immunosuppressants or have compromised immune systems may be at increased risk of serious infections, and physicians need to fully consider the benefit-risk ratio before prescribing denosumab to such patients.

A routine oral examination should be performed before starting denosumab treatment, and good oral hygiene should be maintained after treatment is started. Osteonecrosis of the jaw often occurs with tooth extraction and local infection that delays healing. If a patient develops osteonecrosis of the jaw, treatment for osteonecrosis of the jaw may worsen the condition, and discontinuation of the medication should be considered at this time.

Amgen is principally engaged in the discovery, development, production and sales of innovative drugs for human use, and is committed to exploring the potential of biotechnology for the treatment of patients with serious diseases. As a leader in the global biopharmaceutical industry, Guizhou has strong R&D capabilities and product advantages. It insists on developing in the field of biotechnology for disease treatment. Its main fields include human genome, cancer, neuroscience and small molecule chemistry.

It is China's first and currently the only anti-RANKL monoclonal antibody drug approved for the treatment of osteoporosis. It can help postmenopausal women significantly reduce the risk of vertebral, non-vertebral and hip fractures.